Jennifer La PhD
Adjunct Instructor, Hematology & Medical Oncology
72 E. Concord Street | (617) 638-7012jla2689@bu.edu
Sections
Hematology & Medical Oncology
Education
PhD, University of Chicago
MS, University of Chicago
Pharmacology, BS, Stony Brook University
Publications
Jafari O, Ma S, Lam BD, Jiang JY, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos CI, Oluyomi A, Fillmore NR, La J, Li A. Development and validation of venous thromboembolism-bidirectional encoder representations from transformers (VTE-BERT) natural language processing model. J Thromb Haemost. 2025 Aug 05. PMID: 40754035.
Published on 7/16/2025Lotfollahzadeh S, Jose A, Yang X, Bathla T, Lazowski A, Hoekstra I, Sethuraman K, Potluri S, Dulberger K, La J, Fillmore N, Piqueras MDC, Lee N, Cabral HJ, Ravid K, Chitalia V. Dietary Tryptophan Augments Cancer-Associated Venous Thrombosis Mitigated by Indoleamine 2,3-Dioxygenase 1 Inhibition. Blood Adv. 2025 Jul 16. PMID: 40668615.
Published on 4/8/2025Lee MH, La J, Brophy MT, Do NV, Edwards CV, DuMontier C, Hobbs GS, Fillmore NR. Psychiatric and substance use disorders predict poor outcomes in older veterans with acute myeloid leukemia. Blood Adv. 2025 Apr 08; 9(7):1555-1558. PMID: 39715463.
Published on 4/1/2025Larsen JR, Zheng C, La J, Wu JT, Kelley M, Gaziano JM, Brophy M, Do NV, Kim DH, Driver JA, DuMontier C, Fillmore NR. Multimorbidity and Its Impact in Older U.S. Veterans Newly Treated for Advanced Non-Small Cell Lung Cancer. Ann Am Thorac Soc. 2025 Apr; 22(4):598-608. PMID: 39680869.
Published on 2/21/2025Swinnerton K, Fillmore NR, Vo A, La J, Elbers D, Brophy M, Do NV, Monach PA, Branch-Elliman W. Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool. EClinicalMedicine. 2025 Mar; 81:103114. PMID: 40070694.
Published on 2/3/2025Kim RB, Ryu JH, Guffey D, Zhou E, Ranjan M, Ma S, La J, Fillmore NR, Li A. Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system. J Thromb Haemost. 2025 May; 23(5):1539-1550. PMID: 39909143.
Published on 12/30/2024Wu JT, Corrigan J, Su C, Dumontier C, La J, Khan A, Arya S, Harris AHS, Backhus L, Das M, Do NV, Brophy MT, Han SS, Kelley M, Fillmore NR. Correction: The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2024 Dec 30; 74(1):34. PMID: 39739108.
Published on 12/3/2024Dulberger KN, La J, Li A, Lotfollahzadeh S, Jose A, Do NV, Brophy MT, Gaziano JM, Ravid K, Chitalia VC, Fillmore NR. External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital. Res Pract Thromb Haemost. 2025 Jan; 9(1):102650. PMID: 39839661.
Published on 9/26/2024Ma S, Jiang JY, Kim RB, Chiang E, Theng Tiong JW, Ryu J, Guffey D, Bandyo R, Dowst H, Swinnerton KN, Fillmore NR, La J, Li A. Circulating tumor DNA predicts venous thromboembolism in patients with cancers. J Thromb Haemost. 2025 Jan; 23(1):139-148. PMID: 39341370.
Published on 8/1/2024La J, Wang L, Corrigan JK, Lang D, Lee MH, Do NV, Brophy MT, Paller CJ, Fillmore NR. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2024 Aug 01; 7(8):e2428444. PMID: 39150709.